These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36424294)

  • 21. Pharmacist insights into adolescent human papillomavirus vaccination provision in the United States.
    Islam JY; Gruber JF; Kepka D; Kunwar M; Smith SB; Rothholz MC; Brewer NT; Smith JS
    Hum Vaccin Immunother; 2019; 15(7-8):1839-1850. PubMed ID: 30550369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant HPV and MenACWY vaccination among sixth and seventh graders receiving Tdap.
    Doke K; Fitzgerald SA; Barral RL; Griffin P; Ellerbeck EF
    Vaccine; 2018 Oct; 36(45):6819-6825. PubMed ID: 30266487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using the 4 Pillars™ Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination.
    Zimmerman RK; Raviotta JM; Nowalk MP; Moehling KK; Reis EC; Humiston SG; Lin CJ
    Vaccine; 2017 Oct; 35(45):6180-6186. PubMed ID: 28947346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
    Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
    Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of an immunization check-up at a pharmacist-provided employee health screening.
    Sparkman A; Brookhart AL; Goode JKR
    J Am Pharm Assoc (2003); 2017; 57(3S):S274-S278. PubMed ID: 28366600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of provider recommendation on human papillomavirus vaccine and other adolescent vaccines.
    Caldwell AC; Madden CA; Thompson DM; Garbe MC; Roberts JR; Jacobson RM; Darden PM
    Hum Vaccin Immunother; 2021 Apr; 17(4):1059-1067. PubMed ID: 33074774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.
    Williams WW; Lu PJ; O'Halloran A; Kim DK; Grohskopf LA; Pilishvili T; Skoff TH; Nelson NP; Harpaz R; Markowitz LE; Rodriguez-Lainz A; Bridges CB;
    MMWR Surveill Summ; 2016 Feb; 65(1):1-36. PubMed ID: 26844596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacist impact on pneumococcal polysaccharide vaccination rates in patients with diabetes in a national grocery chain pharmacy.
    Page A; Harrison A; Nadpara P; Goode JR
    J Am Pharm Assoc (2003); 2020; 60(3S):S51-S55.e1. PubMed ID: 32192948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Aug; 59(32):1018-23. PubMed ID: 20724968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A population-level assessment of factors associated with uptake of adolescent-targeted vaccines in Michigan.
    Gowda C; Dong S; Potter RC; Dombkowski KJ; Dempsey AF
    J Adolesc Health; 2013 Oct; 53(4):498-505. PubMed ID: 24054080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination coverage among adolescents aged 13-17 years - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(40):1100-3. PubMed ID: 18846032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adolescent vaccination-coverage levels in the United States: 2006-2009.
    Stokley S; Cohn A; Dorell C; Hariri S; Yankey D; Messonnier N; Wortley PM
    Pediatrics; 2011 Dec; 128(6):1078-86. PubMed ID: 22084326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suboptimal uptake of meningococcal vaccines among older adolescents: Barriers, solutions, and future research directions.
    Niccolai LM; Hansen CE
    Hum Vaccin Immunother; 2020 Dec; 16(12):3208-3212. PubMed ID: 32614695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL
    Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring Adolescent Human Papillomavirus Vaccine Coverage: A Match of Sexually Transmitted Disease Clinic and Immunization Registry Data.
    Pathela P; Jamison K; Papadouka V; Kabir R; Markowitz LE; Dunne EF; Schillinger JA
    J Adolesc Health; 2016 Dec; 59(6):710-715. PubMed ID: 27671357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States.
    Saxena K; Marden JR; Carias C; Bhatti A; Patterson-Lomba O; Gomez-Lievano A; Yao L; Chen YT
    Curr Med Res Opin; 2021 Dec; 37(12):2077-2087. PubMed ID: 34538163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Readiness and Willingness to Provide Immunization Services after Pilot Vaccination Training: A Survey among Community Pharmacists Trained and Not Trained in Immunization during the COVID-19 Pandemic in Poland.
    Merks P; Religioni U; Bilmin K; Lewicki J; Jakubowska M; Waksmundzka-Walczuk A; Czerw A; Barańska A; Bogusz J; Plagens-Rotman K; Świetlik D; Drelich E; Świeczkowski D; Lambert J; Jaguszewski M; Juszczyk G; Balkhi B; Vaillancourt R
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33445750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.